Evidence map›Paper›PMID 33758856›Full record

ArticlebioRxiv : the preprint server for biology2021

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.

Allison J Greaney, Tyler N Starr, Christopher O Barnes, Yiska Weisblum, Fabian Schmidt, Marina Caskey, Christian Gaebler, Alice Cho, Marianna Agudelo, Shlomo Finkin and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Allison J GreaneyBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Tyler N StarrBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Christopher O BarnesDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Yiska WeisblumLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Alice ChoLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Marianna AgudeloLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Shlomo FinkinLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Zijun WangLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Daniel PostonLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Frauke MueckschLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA.
Paul D BieniaszHoward Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Davide F RobbianiLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Michel C NussenzweigHoward Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Rockefeller University · USHoward Hughes Medical Institute · USCalifornia Institute of Technology · USUniversità della Svizzera italiana · CHUniversity of Washington · US

Funding

Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI RAVETCH, JEFFREY VICTOR · 2014 to 2023
$26.0M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
High-throughput experiments to guide influenza vaccine strain selectionR01AI127893 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2016 to 2020
$2.1M
Prospectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
NIAID NIH HHS R01 AI127893NIAID NIH HHS R01 AI141707NIAID NIH HHS T32 AI083203NIAID NIH HHS U01 AI151698NIAID NIH HHS U19 AI111825NIH HHS S10 OD028685
6 · The paper itself

Abstract

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals previously infected with SARS-CoV-2, but the relative contributions of these different antibody classes to the polyclonal response remains unclear. Here we use a yeast-display system to map all mutations to the viral spike receptor-binding domain (RBD) that escape binding by representatives of three potently neutralizing classes of anti-RBD antibodies with high-resolution structures. We compare the antibody-escape maps to similar maps for convalescent polyclonal plasma, including plasma from individuals from whom some of the antibodies were isolated. The plasma-escape maps most closely resemble those of a single class of antibodies that target an epitope on the RBD that includes site E484. Therefore, although the human immune system can produce antibodies that target diverse RBD epitopes, in practice the polyclonal response to infection is dominated by a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

Identifiers

PMID33758856
PMCPMC7987015
OpenAlexW3138251214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.